Category - Developments

The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation...

Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized...

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry...

Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients with Type 2 diabetes...

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollmentin the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide. Last week, the company reached the...

Senseonics Holdings (NYSE-MKT:SENS) has received CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) System. “The CE Mark approval is a significant accomplishment for Senseonics as this application...

First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case. In the first quarter, we invested heavily in new...

Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue...

Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by...

Incyte (NASDAQ:INCY) has agreed to acquire ARIAD Pharmaceuticals’ (NASDAQ:ARIA) European operations. At the expected June 1 closing of the transaction, Incyte will obtain an exclusive license to develop and...